Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa

K. Ray Chaudhuri; Maurizio F. Facheris; Bruno Bergmans; Filip Bergquist; Susan R. Criswell; Jia Jia; Pavnit Kukreja; Yohei Mukai; Amy M. Spiegel; Resmi Gupta; Lars Bergmann; Rajesh Pahwa

doi:10.1002/mdc3.14018

Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa

K. Ray Chaudhuri^*, Maurizio F. Facheris, Bruno Bergmans, Filip Bergquist, Susan R. Criswell, Jia Jia, Pavnit Kukreja, Yohei Mukai, Amy M. Spiegel, Resmi Gupta, Lars Bergmann, Rajesh Pahwa

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs. Objectives: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167). Methods: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and “Off”/“On” times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score. Results: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved “Off” time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, “Off” time, QoL, and m-EDL. Conclusions: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and “Off” time.

Original language	English
Pages (from-to)	861-866
Number of pages	6
Journal	Movement Disorders Clinical Practice
Volume	11
Issue number	7
DOIs	https://doi.org/10.1002/mdc3.14018
Publication status	Published - Jul 2024

Keywords

foslevodopa/foscarbidopa
infusion therapy
Parkinson's disease
post hoc analysis
sleep

Access to Document

10.1002/mdc3.14018

Cite this

@article{ee5399d5c68549a18f1b7664e902da47,

title = "Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa",

abstract = "Background: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs. Objectives: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167). Methods: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and “Off”/“On” times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score. Results: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved “Off” time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, “Off” time, QoL, and m-EDL. Conclusions: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and “Off” time.",

keywords = "foslevodopa/foscarbidopa, infusion therapy, Parkinson's disease, post hoc analysis, sleep",

author = "Chaudhuri, {K. Ray} and Facheris, {Maurizio F.} and Bruno Bergmans and Filip Bergquist and Criswell, {Susan R.} and Jia Jia and Pavnit Kukreja and Yohei Mukai and Spiegel, {Amy M.} and Resmi Gupta and Lars Bergmann and Rajesh Pahwa",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.",

year = "2024",

month = jul,

doi = "10.1002/mdc3.14018",

language = "English",

volume = "11",

pages = "861--866",

journal = "Movement Disorders Clinical Practice",

issn = "2330-1619",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa

AU - Chaudhuri, K. Ray

AU - Facheris, Maurizio F.

AU - Bergmans, Bruno

AU - Bergquist, Filip

AU - Criswell, Susan R.

AU - Jia, Jia

AU - Kukreja, Pavnit

AU - Mukai, Yohei

AU - Spiegel, Amy M.

AU - Gupta, Resmi

AU - Bergmann, Lars

AU - Pahwa, Rajesh

PY - 2024/7

Y1 - 2024/7

N2 - Background: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs. Objectives: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167). Methods: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and “Off”/“On” times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score. Results: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved “Off” time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, “Off” time, QoL, and m-EDL. Conclusions: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and “Off” time.

AB - Background: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs. Objectives: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167). Methods: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and “Off”/“On” times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score. Results: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved “Off” time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, “Off” time, QoL, and m-EDL. Conclusions: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and “Off” time.

KW - foslevodopa/foscarbidopa

KW - infusion therapy

KW - Parkinson's disease

KW - post hoc analysis

KW - sleep

UR - http://www.scopus.com/inward/record.url?scp=85187476728&partnerID=8YFLogxK

U2 - 10.1002/mdc3.14018

DO - 10.1002/mdc3.14018

M3 - Article

AN - SCOPUS:85187476728

SN - 2330-1619

VL - 11

SP - 861

EP - 866

JO - Movement Disorders Clinical Practice

JF - Movement Disorders Clinical Practice

IS - 7

ER -

Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this